Table 1 Baseline characteristics of the study population
From: Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension
SSc-PAH | SSc | Idiopathic PAH | Healthy control | |
|---|---|---|---|---|
N | 18 | 21 | 15 | 14 |
Men/woman (Nof patients) | 2/16 | 3/18 | 5/10 | 3/11 |
Disease duration (years ± SD | 21.1 ± 7.6 | 19.1 ± 9.0 | 20.0 ± 10 | |
Age (mean, years ± SD) | 69.8 ± 8.0 | 60.5 ± 9.3 | 62.5 ± 14.6 | 63.7 ± 10.1 |
lcSSc/dcSSc (Nof patients) | 5/13 | 7/14 | ||
ACA/Scl70 (Nof patients) | 5/13 | 7/14 | ||
Digital ulcers (Nof patients) | 2 | 1 | ||
sPAP eco | 73.1 ± 16.6 | 23.3 ± 4.4 | 68.7 ± 20.5 | |
mPAP RHC | 43.0 ± 10.6 | 49.9 ± 21.0 | ||
mRSS in dcSSc (mean ± SD) | 16.8 ± 2.4 | 10.6 ± 7.1 | ||
mRSS in lcSSc (mean ± SD) | 3.6 ± 2.5 | 3.9 ± 2.3 | ||
Prostanoid | Not | Not | Not | Not |
Calcium-channel blockers | Not | Not | Not | Not |
Phosphodiestererase-5 inhibitors | Not | Not | Not | Not |
Endothelin-1 receptors antagonists | Not | Not | Not | Not |
Vasoactive therapies | Not | Not | Not | Not |